A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia

Inclusion Criteria

INCLUSION CRITERIA:

All patients 1 year and less than 10 years of age.

Patient must be diagnosed with acute lymphoblastic leukemia.

All CCG patients must be enrolled on CCG 1952, 1962 or 1991 protocols, or be treated
according to a CCG standard risk ALL protocol. NCI patients must be treated according to
CCG 1952 for the treatment of standard risk ALL. Enrollment onto the current trial (CCG
B9802) should if possible take place concurrently with enrollment onto 1952/1962/1991 or
start of treatment according to a CCG standard risk ALL protocol.

All patients or their legal guardians must sign a document of informed consent indicating
their awareness of the investigational nature and the risks of this study.

EXCLUSION CRITERIA:

Previous underlying peripheral neuropathy.

Previous underlying central nervous system dysfunction.

Children with CNS toxicity attributable to other chemotherapeutic agents will not be
followed with the Purdue pegboard test.